Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerSept 2 pediatric hemophilia inhibitor study
2015-000958-38Phase 3Completed
- Sponsor
- LFB USA
- Start
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of Coagulation factor VIIa recombinant human in hemophilia A and hemophilia B (HB) (2 arms), sponsored by LFB USA. Primary endpoint: Successful treatment of a bleeding episode at 12 hours after first administration. Started Nov 2015; status: completed.
02
Drugs
Coagulation factor VIIa recombinant human
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2015-000958-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000958-38.